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Introduction There is currently no consensus on the duration of hospita-
lization required after transfemoral transcatheter valve implantation (TF-
TAVI). 
We recently reported, retrospectively, that early discharge (within 3 days)
was feasible in 31% and safe without any death and a low rate of re-hospital-
ization at 30 days. We therefore aimed to confirm the feasibility and safety of
early discharge after TF-TAVI in a prospective study.
Methods After implementation of an early discharge pathway in our center
in January 2014, we included prospectively, between January 2014 and Jan-
uary 2015, 130 consecutive patients scheduled for TF-TAVI with Edwards
prosthesis using exclusively local anesthesia. The primary end-point combined
death and re-hospitalization from discharge to 30-day follow-up. The propor-
tion of early discharge (within 3 days) and the cause of "non-early" discharge
were also assessed.
Results During the studied period, the mean length of stay was 4.0±2.7
days and 76 (58.6%) patients were discharged early within 3 days including
55 (42.3%) patients discharged within 2 days after the procedure. The main
causes of non-early discharge were conduction abnormalities in 33 (25%)
patients, major vascular complications in 18 (13.8%) patients, social issues in
11 (8.5%) patients, heart failure in 3 (2.3%) patients, and acute kidney injury
in 2 (1.5%) patients. Finally, between discharge and 30-day follow-up, there
was no death and only 5 (6.5%) patients required re-hospitalization.
Conclusions Early discharge is feasible in slightly over 50% of cases in
selected patients scheduled for TF-TAVI using a balloon-expandable and local
anesthesia, and is associated with no death and a very low rate of readmission
at 30 days. The two main causes of non-early discharge are occurrence of new
conduction disturbances and major vascular complications.
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Mitral valve prolapse (MVP) by Barlow disease is recognized a genetic
disease. Fibro-elastic deficiency (FED)-MVP is considered a pure degenera-
tive condition. FLNA, the first gene involved in MVP, encodes for Filamin-A,
a cytoskeleton associated protein. It interacts with a protein named Filgap,
encoded by ARHGAP24 (Chr. 4), in the mechanical transduction. We hypoth-
esized that ARHGAP24 mutations could elicit MVP with same pathway.
Four probands with ARHGAP24 mutations were identified among
96 MVP. By a familial echocardiographic screening we enrolled 19 adults of
whom 13 had an ARHGAP24 mutation. The mutated group was matched with
a control group of 39 healthy adults. Anterior (AML) and posterior (PML)
mitral leaflets length and thickness were measured. The coaptation point posi-
tion was the ratio of coaptation height on the systolic annulus diameter. MVP
(displacement >2mm above the annulus line), minimal systolic displacement
(MSD, displacement <2mm) and abnormal antero-posterior coaptation posi-
tion (AAC, ratio <60%) were assessed. 
The conjunction of MSD and AAC defines a MVP prodromal form (MVP-
prod).
There was no difference between the two groups on baseline characteris-
tics. Leaflets were thin in the mutated group (PML: 2.7±1 vs 2.2±0.5mm in
control, P=0.21, AML: 2.5±0.9 vs 2.1±0.4mm, P=0.25), as reported in FED-
MVP. Only the PML was elongated (8.2±1.6 vs 6.0±1.2mm/m2, P=0.0003) in
the mutated group, leading to an anterior displacement of the coaptation point
(51±11 vs 66±7%, P=0.0003). Abnormal mitral phenotype (70% of MVP,
23% of MVP prod) and mitral regurgitation (93 vs 38%, P=0.0007) were fre-
quent in the mutated group. Two probands were operated for severe MR
related to chordal rupture; histological examination confirmed the leaflets
thinness.
ARHGAP24 is the first gene for autosomal dominant inherited MVP. Our
limited series of patients exhibit typical features of FED-MVP. Our results
could change the paradigm of a pure degenerative disease for FED-MVP.
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Studies that investigate the secretion of BNP in diseases affecting the
atrium are rare. The relationship between N-terminal proBNP (NT-proBNP)
and the echocardiographic (TTE) and hemodynamic data were studied in cases
of pure and isolated rheumatic mitral stenosis (RMS). 67 patients with MS
(41±11 years), and 29 healthy individuals (age 36±11 years) were included in
the study. Detailed TTE was performed before, one and six months after PMC
.we measured NT pro BNP in systemic venous and left atrial (LA) before,
immediately after, and one and 30 days after the procedure. 
Results The plasma levels of NT-proBNP were significantly higher in MS
patients than in controls (103.2±116.8 VS 21.5±8.5pg/mL, p=0.004).We
revealed a strong correlation between levels of NT pro-BNP in peripheral vein
(PV) and in LA (r=0.819, p=0.001). NT-proBNP was higher in the LA than
PV. We releaved a positive correlation with LA volume (0.470, p=0.001 and
p=0.001, 0.681 respectively at the LA and at the PV), the absolute value of
LV strain (r=0.524, p=0.001 and r=0.568, p=0.001) and the pulmonary artery
pression (PAP) (r =0.312, p=0.01 and r=0.586 p=0.001). Negative correlations
with LVEF (r=–0.421, p=0.001 and r=-0,462, p=0.000) and the longitudinal
movement of the VD (r=-0,380, p=0.002 and r=–0,374, p=0.001) were
observed. NT pro BNP falls immediately after PMC IN the sinus rythm (SR)
group patients but not in the atrial fibrillation (AF) group. Moreover, LA
remodeling at six months is more pronounced in SR (SOG=0.04±0.07 VS
0.02±0.06 in the AF group; LA volume=5.94±6.5 VS 1.17±8.6
Conclusion In patients with RMS, NT-proBNP was positively correlated
with LA enlargement and the PAP and could be a valuable marker to reflect
the structural changes of the LA aftercmP, in patients with SR but not in those
with AF.
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Background Mitral annular calcifications (MAC) is a common finding in
elder patients referred for transcatheter aortic valve implantation (TAVI),
sometimes responsible of significant degenerative calcified mitral stenosis
